Annual CFO
-$32.16 M
+$4.54 M+12.37%
31 December 2023
Summary:
Oncternal Therapeutics annual cash flow from operations is currently -$32.16 million, with the most recent change of +$4.54 million (+12.37%) on 31 December 2023. During the last 3 years, it has fallen by -$14.67 million (-83.85%). ONCT annual CFO is now -40305.00% below its all-time high of $80.00 thousand, reached on 31 December 2000.ONCT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.95 M
-$1.13 M-19.43%
30 September 2024
Summary:
Oncternal Therapeutics quarterly cash flow from operations is currently -$6.95 million, with the most recent change of -$1.13 million (-19.43%) on 30 September 2024. Over the past year, it has dropped by -$1.44 million (-26.12%). ONCT quarterly CFO is now -124.22% below its all-time high of $28.70 million, reached on 31 March 2008.ONCT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$26.63 M
-$1.44 M-5.72%
30 September 2024
Summary:
Oncternal Therapeutics TTM cash flow from operations is currently -$26.63 million, with the most recent change of -$1.44 million (-5.72%) on 30 September 2024. Over the past year, it has increased by +$8.12 million (+23.35%). ONCT TTM CFO is now -4483.82% below its all-time high of -$581.00 thousand, reached on 31 March 2008.ONCT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ONCT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.4% | -26.1% | +23.4% |
| 3 y3 years | -83.8% | -9.0% | -11.5% |
| 5 y5 years | +18.3% | -81.6% | -14.2% |
ONCT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.8% | +12.4% | -26.1% | +41.9% | -11.5% | +35.4% |
| 5 y | 5 years | -92.1% | +18.3% | -128.3% | +41.9% | -97.1% | +35.4% |
| alltime | all time | <-9999.0% | +30.1% | -124.2% | +54.6% | -4483.8% | +43.3% |
Oncternal Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.95 M(+19.4%) | -$26.63 M(+5.7%) |
| June 2024 | - | -$5.82 M(-21.7%) | -$25.19 M(-12.0%) |
| Mar 2024 | - | -$7.44 M(+15.9%) | -$28.63 M(-11.0%) |
| Dec 2023 | -$32.16 M(-12.4%) | -$6.42 M(+16.4%) | -$32.16 M(-7.4%) |
| Sept 2023 | - | -$5.51 M(-40.5%) | -$34.75 M(-15.7%) |
| June 2023 | - | -$9.26 M(-15.6%) | -$41.20 M(+5.5%) |
| Mar 2023 | - | -$10.97 M(+21.9%) | -$39.07 M(+6.4%) |
| Dec 2022 | -$36.70 M(+38.0%) | -$9.00 M(-24.8%) | -$36.70 M(+7.0%) |
| Sept 2022 | - | -$11.97 M(+67.8%) | -$34.32 M(+19.4%) |
| June 2022 | - | -$7.13 M(-17.2%) | -$28.73 M(-1.6%) |
| Mar 2022 | - | -$8.61 M(+30.1%) | -$29.21 M(+9.9%) |
| Dec 2021 | -$26.59 M(+52.0%) | -$6.62 M(+3.7%) | -$26.59 M(+11.3%) |
| Sept 2021 | - | -$6.38 M(-16.1%) | -$23.88 M(+4.6%) |
| June 2021 | - | -$7.61 M(+27.1%) | -$22.83 M(+17.4%) |
| Mar 2021 | - | -$5.99 M(+53.0%) | -$19.44 M(+11.1%) |
| Dec 2020 | -$17.50 M(+4.5%) | -$3.91 M(-26.6%) | -$17.50 M(+5.2%) |
| Sept 2020 | - | -$5.33 M(+26.2%) | -$16.63 M(+9.9%) |
| June 2020 | - | -$4.22 M(+4.6%) | -$15.13 M(+12.0%) |
| Mar 2020 | - | -$4.04 M(+32.5%) | -$13.51 M(-19.3%) |
| Dec 2019 | -$16.75 M(-57.4%) | -$3.04 M(-20.5%) | -$16.75 M(-28.2%) |
| Sept 2019 | - | -$3.83 M(+47.2%) | -$23.32 M(-14.3%) |
| June 2019 | - | -$2.60 M(-64.2%) | -$27.20 M(-23.4%) |
| Mar 2019 | - | -$7.27 M(-24.4%) | -$35.51 M(-9.8%) |
| Dec 2018 | -$39.35 M(+67.7%) | -$9.62 M(+24.6%) | -$39.35 M(-0.3%) |
| Sept 2018 | - | -$7.72 M(-29.2%) | -$39.46 M(+12.4%) |
| June 2018 | - | -$10.90 M(-1.9%) | -$35.12 M(+19.6%) |
| Mar 2018 | - | -$11.11 M(+14.2%) | -$29.37 M(+25.2%) |
| Dec 2017 | -$23.46 M(+12.9%) | -$9.73 M(+188.5%) | -$23.46 M(+23.5%) |
| Sept 2017 | - | -$3.37 M(-34.6%) | -$18.99 M(-13.2%) |
| June 2017 | - | -$5.16 M(-0.9%) | -$21.87 M(+3.1%) |
| Mar 2017 | - | -$5.20 M(-1.1%) | -$21.20 M(+2.1%) |
| Dec 2016 | -$20.78 M(+3.7%) | -$5.26 M(-15.9%) | -$20.78 M(+0.3%) |
| Sept 2016 | - | -$6.25 M(+39.2%) | -$20.72 M(+6.6%) |
| June 2016 | - | -$4.49 M(-5.9%) | -$19.44 M(-3.3%) |
| Mar 2016 | - | -$4.78 M(-8.2%) | -$20.11 M(+0.4%) |
| Dec 2015 | -$20.04 M(-30.3%) | -$5.20 M(+4.6%) | -$20.04 M(+0.7%) |
| Sept 2015 | - | -$4.97 M(-3.6%) | -$19.89 M(-3.6%) |
| June 2015 | - | -$5.16 M(+9.9%) | -$20.63 M(-18.7%) |
| Mar 2015 | - | -$4.70 M(-7.2%) | -$25.37 M(-11.8%) |
| Dec 2014 | -$28.76 M(-34.6%) | -$5.06 M(-11.4%) | -$28.76 M(-8.3%) |
| Sept 2014 | - | -$5.71 M(-42.2%) | -$31.35 M(-14.5%) |
| June 2014 | - | -$9.90 M(+22.4%) | -$36.67 M(-3.8%) |
| Mar 2014 | - | -$8.09 M(+5.7%) | -$38.13 M(-13.3%) |
| Dec 2013 | -$43.97 M | -$7.65 M(-30.7%) | -$43.97 M(-5.2%) |
| Sept 2013 | - | -$11.04 M(-2.8%) | -$46.38 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2013 | - | -$11.36 M(-18.4%) | -$43.95 M(+8.4%) |
| Mar 2013 | - | -$13.92 M(+38.3%) | -$40.52 M(+9.2%) |
| Dec 2012 | -$37.11 M(+12.1%) | -$10.06 M(+17.0%) | -$37.11 M(+4.3%) |
| Sept 2012 | - | -$8.60 M(+8.4%) | -$35.58 M(+2.0%) |
| June 2012 | - | -$7.93 M(-24.5%) | -$34.89 M(+1.5%) |
| Mar 2012 | - | -$10.51 M(+23.1%) | -$34.37 M(+3.9%) |
| Dec 2011 | -$33.09 M(+8.4%) | -$8.54 M(+8.1%) | -$33.09 M(+27.7%) |
| Sept 2011 | - | -$7.90 M(+6.5%) | -$25.90 M(-2.7%) |
| June 2011 | - | -$7.42 M(-19.6%) | -$26.63 M(-9.8%) |
| Mar 2011 | - | -$9.23 M(+582.1%) | -$29.51 M(-3.3%) |
| Dec 2010 | -$30.53 M(-33.6%) | -$1.35 M(-84.3%) | -$30.53 M(-14.0%) |
| Sept 2010 | - | -$8.63 M(-16.3%) | -$35.49 M(-8.2%) |
| June 2010 | - | -$10.30 M(+0.6%) | -$38.67 M(-5.5%) |
| Mar 2010 | - | -$10.24 M(+62.2%) | -$40.94 M(-11.0%) |
| Dec 2009 | -$46.00 M(+1472.5%) | -$6.32 M(-46.5%) | -$46.00 M(+0.1%) |
| Sept 2009 | - | -$11.80 M(-6.2%) | -$45.96 M(+1.8%) |
| June 2009 | - | -$12.58 M(-17.8%) | -$45.16 M(-3.8%) |
| Mar 2009 | - | -$15.30 M(+143.5%) | -$46.93 M(+1504.4%) |
| Dec 2008 | -$2.92 M(-92.2%) | -$6.29 M(-42.8%) | -$2.92 M(-49.5%) |
| Sept 2008 | - | -$11.00 M(-23.3%) | -$5.80 M(-0.9%) |
| June 2008 | - | -$14.35 M(-150.0%) | -$5.85 M(+906.9%) |
| Mar 2008 | - | $28.70 M(-413.4%) | -$581.00 K(-98.5%) |
| Dec 2007 | -$37.63 M(+228.4%) | -$9.16 M(-17.1%) | -$37.63 M(+244.4%) |
| Sept 2007 | - | -$11.05 M(+21.7%) | -$10.93 M(+1.9%) |
| June 2007 | - | -$9.08 M(+8.7%) | -$10.72 M(-5.5%) |
| Mar 2007 | - | -$8.35 M(-147.6%) | -$11.35 M(-1.0%) |
| Dec 2006 | -$11.46 M(-67.1%) | $17.55 M(-261.8%) | -$11.46 M(-70.1%) |
| Sept 2006 | - | -$10.84 M(+11.8%) | -$38.27 M(+2.3%) |
| June 2006 | - | -$9.70 M(+14.7%) | -$37.42 M(+8.2%) |
| Mar 2006 | - | -$8.46 M(-8.7%) | -$34.57 M(-0.7%) |
| Dec 2005 | -$34.82 M(+122.2%) | -$9.27 M(-7.2%) | -$34.82 M(+8.2%) |
| Sept 2005 | - | -$9.99 M(+45.7%) | -$32.18 M(+17.8%) |
| June 2005 | - | -$6.86 M(-21.3%) | -$27.32 M(+44.6%) |
| Mar 2005 | - | -$8.71 M(+31.5%) | -$18.90 M(+20.6%) |
| Dec 2004 | -$15.67 M(+20.6%) | -$6.62 M(+29.0%) | -$15.67 M(+20.7%) |
| Sept 2004 | - | -$5.13 M(-428.0%) | -$12.98 M(+16.6%) |
| June 2004 | - | $1.56 M(-128.6%) | -$11.14 M(-29.7%) |
| Mar 2004 | - | -$5.48 M(+39.3%) | -$15.85 M(+21.9%) |
| Dec 2003 | -$13.00 M(+23.2%) | -$3.93 M(+19.6%) | -$13.00 M(+43.4%) |
| Sept 2003 | - | -$3.29 M(+4.6%) | -$9.06 M(+57.0%) |
| June 2003 | - | -$3.15 M(+19.6%) | -$5.77 M(+119.6%) |
| Mar 2003 | - | -$2.63 M | -$2.63 M |
| Dec 2002 | -$10.55 M(<-9900.0%) | - | - |
| Dec 2000 | $80.00 K(+77.8%) | - | - |
| Dec 1999 | $45.00 K | - | - |
FAQ
- What is Oncternal Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual CFO year-on-year change?
- What is Oncternal Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly CFO year-on-year change?
- What is Oncternal Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Oncternal Therapeutics?
- What is Oncternal Therapeutics TTM CFO year-on-year change?
What is Oncternal Therapeutics annual cash flow from operations?
The current annual CFO of ONCT is -$32.16 M
What is the all time high annual CFO for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual cash flow from operations is $80.00 K
What is Oncternal Therapeutics annual CFO year-on-year change?
Over the past year, ONCT annual cash flow from operations has changed by +$4.54 M (+12.37%)
What is Oncternal Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ONCT is -$6.95 M
What is the all time high quarterly CFO for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly cash flow from operations is $28.70 M
What is Oncternal Therapeutics quarterly CFO year-on-year change?
Over the past year, ONCT quarterly cash flow from operations has changed by -$1.44 M (-26.12%)
What is Oncternal Therapeutics TTM cash flow from operations?
The current TTM CFO of ONCT is -$26.63 M
What is the all time high TTM CFO for Oncternal Therapeutics?
Oncternal Therapeutics all-time high TTM cash flow from operations is -$581.00 K
What is Oncternal Therapeutics TTM CFO year-on-year change?
Over the past year, ONCT TTM cash flow from operations has changed by +$8.12 M (+23.35%)